Clinical Trial Detail

NCT ID NCT03165734
Title A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors CTI BioPharma
Indications

myelofibrosis

Therapies

Lenalidomide

Ruxolitinib

Hydroxyurea

Pacritinib

Thalidomide

Age Groups: adult senior

No variant requirements are available.